Signup to have metrics tracked for this article

By signing up, social media discussions about Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain. will be collected and displayed on PubHawk. We'll also notify you by email on a monthly basis of any new updates captured on platforms like YouTube, Twitter/X, Bluesky, Facebook, LinkedIn, and more.
Your identifiable personal information will never be sold or shared to directly target you.

Please enter a valid email.
You must agree before submitting.

Example of Metrics tracking for this article:

Layout example
Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.
Layout example